Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omid Hamid

Showing results (61-70 of 188) with videos related to

Pageof 19
Sort By:
Journal of Translational Medicine|April 18, 2020
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019Paolo A Ascierto, Sanjiv S Agarwala, Alexander Eggermont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV MelanomaIgor Puzanov, Mohammed M Milhem, David Minor, et al.
JAMA Surgery|September 1, 2021
Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous MelanomaAnthony T Nguyen, Michael Luu, Vina P Nguyen, et al.
British Journal of Cancer|March 22, 2017
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapyAdi Nosrati, Katy K Tsai, Simone M Goldinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancerRobert Dreicer, David MacLean, Ajit Suri, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 14, 2014
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer typeZoran Gatalica, Carrie Snyder, Todd Maney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanomaPatrick A Ott, Omid Hamid, Anna C Pavlick, et al.
British Journal of Cancer|September 12, 2018
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006Omid Hamid, Caroline Robert, Antoni Ribas, et al.
Frontiers in Oncology|June 7, 2014
Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 LevelsAnna M Leung, Agnes Fermin Lee, Junko Ozao-Choy, et al.
Cancer Chemotherapy and Pharmacology|January 7, 2014
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignanciesDaruka Mahadevan, Gregory Ryan Sutton, Rafael Arteta-Bulos, et al.
Pageof 19

Showing results (61-70 of 188) with videos related to

Sort By:
Pageof 19
Journal of Translational Medicine|April 18, 2020
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019Paolo A Ascierto, Sanjiv S Agarwala, Alexander Eggermont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV MelanomaIgor Puzanov, Mohammed M Milhem, David Minor, et al.
JAMA Surgery|September 1, 2021
Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous MelanomaAnthony T Nguyen, Michael Luu, Vina P Nguyen, et al.
British Journal of Cancer|March 22, 2017
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapyAdi Nosrati, Katy K Tsai, Simone M Goldinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancerRobert Dreicer, David MacLean, Ajit Suri, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 14, 2014
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer typeZoran Gatalica, Carrie Snyder, Todd Maney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanomaPatrick A Ott, Omid Hamid, Anna C Pavlick, et al.
British Journal of Cancer|September 12, 2018
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006Omid Hamid, Caroline Robert, Antoni Ribas, et al.
Frontiers in Oncology|June 7, 2014
Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 LevelsAnna M Leung, Agnes Fermin Lee, Junko Ozao-Choy, et al.
Cancer Chemotherapy and Pharmacology|January 7, 2014
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignanciesDaruka Mahadevan, Gregory Ryan Sutton, Rafael Arteta-Bulos, et al.
Pageof 19